Uniqure N.V. (QURE)

$65.90 +4.89 (8.02%)
Market Cap 3.35B
Revenue (ttm) 27.12M
Net Income (ttm) -239.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -883.33%
Debt to Equity Ratio -12.96
Volume 1,527,552
Avg Vol 3,817,424
Day's Range N/A - N/A
Shares Out 54.87M
Stochastic %K 45%
Beta 0.56
Analysts Strong Sell
Price Target $75.50

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
Lincoln1962
Lincoln1962 Oct. 27 at 4:57 PM
$QURE
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 27 at 4:12 PM
$QURE this is primed and ready to be bought.
0 · Reply
Albino_Trader123
Albino_Trader123 Oct. 27 at 2:03 PM
$QURE Looks ready here. Have some longs in
0 · Reply
snowboy
snowboy Oct. 26 at 4:31 PM
$CAPR Busy couple of weeks upcoming for Linda and team. Please remember that the gene nerds at $SRPT and others will be needed for true cures. Once concept of exosome-based treatment proved, work will start on using StealthX platform to float gene therapies to muscles so that the damned AAV vectors and their incipient side effects can be ditched. ​For instance, $QURE will be able to float Huntingdon gene fix to brain using IV administered exosome carrier, eliminating manual placement in brain via surgery. I am remaining incredibly long investor from here... $40 billion MC or buyout. 30 minutes to kickoff. See ya at Thanksgiving.
0 · Reply
Jadek6
Jadek6 Oct. 26 at 2:58 PM
$QURE ..poor little DOOM ..caught in his repeated CON's
0 · Reply
Jadek6
Jadek6 Oct. 26 at 1:59 PM
$QURE. Con man is back ..he is already selling , posters !!!
1 · Reply
MF__DOOM
MF__DOOM Oct. 25 at 10:52 PM
$QURE hold $SPY $QQQ
0 · Reply
HScottMatusow
HScottMatusow Oct. 25 at 12:05 AM
It's actually kinda funny reading X and Stocktwit posts from bears on $QURE. If you going to attempt a bear case, stop using data from 2 years ago, use current data, and stop calling Gene Therapy "a drug." Thank you for playing! $XBI $IBB $IWM $SPY
0 · Reply
UnicornProfits
UnicornProfits Oct. 24 at 8:33 PM
What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $NEON $LAC $QURE $PLRZ bought dips
1 · Reply
Okadarlan
Okadarlan Oct. 22 at 2:26 PM
$QURE ok i short here.
0 · Reply
Latest News on QURE
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood

Oct 8, 2025, 3:33 PM EDT - 18 days ago

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Sep 29, 2025, 4:05 PM EDT - 27 days ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure Announces Pricing of Upsized $300 Million Public Offering

Sep 25, 2025, 11:38 PM EDT - 4 weeks ago

uniQure Announces Pricing of Upsized $300 Million Public Offering

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

Sep 25, 2025, 8:37 AM EDT - 4 weeks ago

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

uniQure Stock Jumps On Positive News, But Risks Remain

Sep 25, 2025, 7:23 AM EDT - 4 weeks ago

uniQure Stock Jumps On Positive News, But Risks Remain

UniQure: How QURE Stock Rises 10x To $500?

Sep 25, 2025, 6:20 AM EDT - 4 weeks ago

UniQure: How QURE Stock Rises 10x To $500?

Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it

Sep 24, 2025, 4:37 PM EDT - 4 weeks ago

Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

Sep 24, 2025, 4:24 PM EDT - 4 weeks ago

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

uniQure Announces $200 Million Proposed Public Offering

Sep 24, 2025, 4:06 PM EDT - 4 weeks ago

uniQure Announces $200 Million Proposed Public Offering

uniQure N.V. - Special Call

Sep 24, 2025, 1:03 PM EDT - 4 weeks ago

uniQure N.V. - Special Call

QURE stock skyrockets 200% on ‘three' big news

Sep 24, 2025, 11:20 AM EDT - 4 weeks ago

QURE stock skyrockets 200% on ‘three' big news

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

Sep 24, 2025, 10:23 AM EDT - 4 weeks ago

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

UniQure's brain disorder drug slows disease progression in trial

Sep 24, 2025, 7:28 AM EDT - 4 weeks ago

UniQure's brain disorder drug slows disease progression in trial

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

Sep 24, 2025, 7:10 AM EDT - 4 weeks ago

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

Sep 24, 2025, 7:05 AM EDT - 4 weeks ago

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data

Sep 5, 2025, 4:57 PM EDT - 7 weeks ago

uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Sep 5, 2025, 7:05 AM EDT - 7 weeks ago

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA RCKT

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 9:07 PM EDT - 3 months ago

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Jul 29, 2025, 7:05 AM EDT - 3 months ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:05 AM EDT - 3 months ago

uniQure to Announce Second Quarter 2025 Financial Results

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

Jun 11, 2025, 8:00 AM EDT - 4 months ago

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Jun 2, 2025, 7:05 AM EDT - 5 months ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

May 28, 2025, 4:56 AM EDT - 5 months ago

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX CRBP

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:16 PM EDT - 6 months ago

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025, 7:05 AM EDT - 6 months ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

May 8, 2025, 5:16 AM EDT - 6 months ago

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 6 months ago

uniQure to Announce First Quarter 2025 Financial Results

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

Apr 21, 2025, 1:56 AM EDT - 6 months ago

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Apr 19, 2025, 8:31 AM EDT - 6 months ago

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

Apr 17, 2025, 10:27 AM EDT - 6 months ago

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

Apr 17, 2025, 7:17 AM EDT - 6 months ago

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

Feb 27, 2025, 7:05 AM EST - 8 months ago

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V.: A Potential Huntington's Play

Feb 26, 2025, 1:47 AM EST - 8 months ago

uniQure N.V.: A Potential Huntington's Play

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

Feb 20, 2025, 3:07 PM EST - 8 months ago

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Feb 7, 2025, 1:04 PM EST - 9 months ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Feb 7, 2025, 9:12 AM EST - 9 months ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Feb 3, 2025, 7:05 AM EST - 9 months ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Jan 30, 2025, 7:37 AM EST - 9 months ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

Jan 8, 2025, 7:05 AM EST - 10 months ago

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

Jan 7, 2025, 4:49 PM EST - 10 months ago

uniQure Announces Proposed Public Offering

Final Trade: DVN, QURE, GOOGL, DFH

Dec 30, 2024, 6:31 PM EST - 10 months ago

Final Trade: DVN, QURE, GOOGL, DFH

GOOG GOOGL DFH DVN

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

Dec 10, 2024, 7:05 AM EST - 11 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Nov 21, 2024, 7:05 AM EST - 1 year ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:05 AM EST - 1 year ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

Oct 15, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

Sep 23, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Aug 15, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 6, 2024, 3:03 AM EDT - 1 year ago

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Lincoln1962
Lincoln1962 Oct. 27 at 4:57 PM
$QURE
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 27 at 4:12 PM
$QURE this is primed and ready to be bought.
0 · Reply
Albino_Trader123
Albino_Trader123 Oct. 27 at 2:03 PM
$QURE Looks ready here. Have some longs in
0 · Reply
snowboy
snowboy Oct. 26 at 4:31 PM
$CAPR Busy couple of weeks upcoming for Linda and team. Please remember that the gene nerds at $SRPT and others will be needed for true cures. Once concept of exosome-based treatment proved, work will start on using StealthX platform to float gene therapies to muscles so that the damned AAV vectors and their incipient side effects can be ditched. ​For instance, $QURE will be able to float Huntingdon gene fix to brain using IV administered exosome carrier, eliminating manual placement in brain via surgery. I am remaining incredibly long investor from here... $40 billion MC or buyout. 30 minutes to kickoff. See ya at Thanksgiving.
0 · Reply
Jadek6
Jadek6 Oct. 26 at 2:58 PM
$QURE ..poor little DOOM ..caught in his repeated CON's
0 · Reply
Jadek6
Jadek6 Oct. 26 at 1:59 PM
$QURE. Con man is back ..he is already selling , posters !!!
1 · Reply
MF__DOOM
MF__DOOM Oct. 25 at 10:52 PM
$QURE hold $SPY $QQQ
0 · Reply
HScottMatusow
HScottMatusow Oct. 25 at 12:05 AM
It's actually kinda funny reading X and Stocktwit posts from bears on $QURE. If you going to attempt a bear case, stop using data from 2 years ago, use current data, and stop calling Gene Therapy "a drug." Thank you for playing! $XBI $IBB $IWM $SPY
0 · Reply
UnicornProfits
UnicornProfits Oct. 24 at 8:33 PM
What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $NEON $LAC $QURE $PLRZ bought dips
1 · Reply
Okadarlan
Okadarlan Oct. 22 at 2:26 PM
$QURE ok i short here.
0 · Reply
stockwitsuser2449
stockwitsuser2449 Oct. 20 at 6:05 PM
$HUMA I want to one day wake up and see this pass $QURE :)
0 · Reply
daticecold
daticecold Oct. 20 at 5:58 PM
$QURE People who are short this stock shouldn't be allowed to operate heavy machinery.
0 · Reply
biotech
biotech Oct. 20 at 5:37 PM
$SGMO $TSHA $QURE
1 · Reply
pnchv59
pnchv59 Oct. 20 at 2:16 PM
$QURE Big buy orders 😳
0 · Reply
SlovedJBandMe
SlovedJBandMe Oct. 20 at 10:17 AM
$QURE Why is QURE showing up as QUOTE on my feed????
0 · Reply
LarsonLE1
LarsonLE1 Oct. 20 at 2:59 AM
$QURE bye bye bears
1 · Reply
CantNameThatTune
CantNameThatTune Oct. 19 at 2:35 PM
$RANI $ASMB $QNRX $QURE $IMRX But let's take it a step farther... RANI pre-funded warrants 82 million @ $.48 and exercisable at $.0001 ASMB pre funded warrants Class A + B prefunded warrants at $19.60 below the $21.60 offer price QNRX pre funded warrants This is a nightmare. Series H, I, J, K prefunded warrants for $88 million QURE pre funded warrants 526K @$47.50 and exercisable at $.0001 IMRX pre funded warrants on 8/21 as part of $25 mil PP (secret investor) at $3.95, with option in at $5.50. Stock walks 4.70 to new highs $10+. Then another round on 9/25 with Sanofi $25 mil PP at $9.23 on the heels of "extroardinary" results per the company. For this one, stock more than doubles on a $25 mil private placement to unknown investor. Then a month later they announce another $25 mil private placement from Sanofi and stock drops 40%. Who really knows anything at this point!
0 · Reply
CantNameThatTune
CantNameThatTune Oct. 19 at 11:44 AM
Let's look at the biotech landscape: $RANI Licensing deal Fri w/Chugai ($CHGCY). $60 mil PIPE w/pre-funded warrants. Up 250%. No trial results $ASMB (Hep B+D) 8/25 announces 94% reduction in Hep at 350 mil dose. Announces $175 mil offer at $19.60 with Gilead separate $45 mil at $19.60. Never went red. New 52 highs Fri @ $30.20 $QNRX (Netherton -extremely rare) No trial news. Announces PP on 10/10 in $7's. Stock runs to $41. Now $16's. Up more than 100% $QURE (Huntingtons - extremely rare) on 9/24 announces some trial progression for AMT-130. Stock runs $13's to $50 . Immed announce $200 mil offering. Upsized to $350 mil. Stock hits new 52's last wk $64. $IMRX (Pancreatic cancer) On 9/25 announces world's best survival rate at 6 mos of 94%. Further announcing survival rate of 86% at 9 mos vs. only FDA approved 42% in the market. Announces $175 mil offering with PP from Sanofi $25 mil. Identical to ASMB. Offering & placement @ $9.23 (no discount). Stock now $5.58
1 · Reply
Paraboljoker
Paraboljoker Oct. 18 at 3:16 PM
$SUGP continues to stand out as one of the cleanest small-cap structures on the market. ✅ Market Cap: Only ~$12.5M ✅ Float: ~0.4M shares — ultra low supply ✅ Cash Need: Low ✅ Overall Risk: Low ✅ Overhead Supply: Low ✅ Estimated Net Cash/Share: $2.97 With minimal dilution risk and positive revenue growth, SUGP is positioned perfectly for a potential momentum run once liquidity returns to the name. This is the type of setup traders look for — tight float, solid fundamentals, clean balance sheet, and real business operations. If growth continues alongside contract expansion, this could reprice quickly. $OPEN $SLNH $QURE $IVF
0 · Reply
Dkll303
Dkll303 Oct. 18 at 1:04 PM
$QURE $SGMO $TSHA cantor is the world's worst at very thing they touch , including but not limited to 1) how. Tariffs are legally initiated, lol 2) who pays for Lutnick’s illegal idea of tariffs No more needed to be said …Low , scum , investment house
1 · Reply
biotech
biotech Oct. 18 at 11:56 AM
$SGMO Cantor says $TSHA roughly 1/3 $QURE market cap despite both: latestage derisking data regulatory support both sizable rare disease markets $QURE ~5-6K patients vs ~10K patients for $TSHA i say same goes for $SGMO but with 25K+ Fabry patients $SGMO marketcap 190M or 1/17 $QURE
0 · Reply
Capitulation_0
Capitulation_0 Oct. 17 at 7:52 PM
$QURE odd $NKTR too
0 · Reply